• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与氨基己酸治疗相关的脑血栓形成。

Cerebral thrombosis associated with Amicar therapy.

作者信息

Hoffman E P, Koo A H

出版信息

Radiology. 1979 Jun;131(3):687-9. doi: 10.1148/131.3.687.

DOI:10.1148/131.3.687
PMID:441374
Abstract

Amicar (epsilon-aminocaproic acid) has been used in patients with subarachnoid hemorrhage to promote clotting. However, cerebral thrombosis has been reported in various vascular compartments following its use. The authors describe 2 patients who had cerebral angiography after Amicar therapy and demonstrated thrombosis unrelated to vascular spasm or technical complications of angiography. Careful screening is needed in patients treated with Amicar to determine if an increased risk of thrombosis exists.

摘要

氨基己酸已被用于蛛网膜下腔出血患者以促进凝血。然而,在使用该药后,已报道在不同血管腔出现脑血栓形成。作者描述了2例在接受氨基己酸治疗后进行脑血管造影的患者,结果显示血栓形成与血管痉挛或血管造影技术并发症无关。对于接受氨基己酸治疗的患者,需要仔细筛查以确定是否存在血栓形成风险增加的情况。

相似文献

1
Cerebral thrombosis associated with Amicar therapy.与氨基己酸治疗相关的脑血栓形成。
Radiology. 1979 Jun;131(3):687-9. doi: 10.1148/131.3.687.
2
Arteriopathic complications during treatment of subarachnoid hemorrhage with epsilon-aminocaproic acid.用ε-氨基己酸治疗蛛网膜下腔出血期间的动脉病变并发症。
J Neurosurg. 1974 Apr;40(4):480-5. doi: 10.3171/jns.1974.40.4.0480.
3
Spontaneous subarachnoid hemorrhage complicated by communicating hydrocephalus: epsilon amino caproic acid as a possible predisposing factor.
Surg Neurol. 1979 Jan;11(1):73-80.
4
Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report.与氨基己酸治疗及急性肾动脉血栓形成相关的复发性蛛网膜下腔出血。病例报告。
J Neurosurg. 1979 Jul;51(1):94-7. doi: 10.3171/jns.1979.51.1.0094.
5
Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition.接受ε-氨基己酸治疗的颅内动脉瘤破裂患者血浆纤溶活性的定量测定:治疗可能并发症与纤溶抑制程度的关系
Neurosurgery. 1984 Jan;14(1):57-63. doi: 10.1227/00006123-198401000-00012.
6
Myopathy associated with epsilon-aminocaproic acid (EACA) therapy. Report of two cases.与ε-氨基己酸(EACA)治疗相关的肌病。两例报告。
J Neurosurg. 1978 Oct;49(4):597-601. doi: 10.3171/jns.1978.49.4.0597.
7
[Letter: Thrombotic complications in cases of subarachnoid hemorrhages treated with epsilon-aminocaproic acid].[信件:用ε-氨基己酸治疗蛛网膜下腔出血病例中的血栓形成并发症]
Neurol Neurochir Pol. 1976 May-Jun;10(3):435-6.
8
Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.脑静脉窦血栓形成作为月经过多抗纤溶治疗的潜在危害。
Stroke. 1990 May;21(5):817-9. doi: 10.1161/01.str.21.5.817.
9
Myoglobinuria following epsilon-aminocaproic acid (EACA) therapy. Case report.
J Neurosurg. 1980 Nov;53(5):690-2. doi: 10.3171/jns.1980.53.5.0690.
10
Experimental epsilon-aminocaproic acid (EACA) administration in the presence of subarachnoid blood.在蛛网膜下腔出血情况下进行实验性氨甲环酸(EACA)给药。
J Neurosurg. 1971 Dec;35(6):657-63. doi: 10.3171/jns.1971.35.6.0657.

引用本文的文献

1
Bioactive hemostatic materials: a new strategy for promoting wound healing and tissue regeneration.生物活性止血材料:促进伤口愈合和组织再生的新策略。
MedComm (2020). 2025 Mar 22;6(4):e70113. doi: 10.1002/mco2.70113. eCollection 2025 Apr.
2
Interstitial plasmin activity with epsilon aminocaproic acid: temporal and regional heterogeneity.伴用 ε-氨基己酸的间质纤维蛋白溶酶活性:时间和区域异质性。
Ann Thorac Surg. 2010 May;89(5):1538-45. doi: 10.1016/j.athoracsur.2010.01.051.
3
Temporally and regionally disparate differences in plasmin activity by tranexamic acid.
氨甲环酸对纤溶酶活性的时空差异。
Anesth Analg. 2010 Mar 1;110(3):694-701. doi: 10.1213/ANE.0b013e3181c7eb27.
4
Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage.抗纤维蛋白溶解疗法预防蛛网膜下腔出血后早期再出血
Neurocrit Care. 2008;8(3):418-26. doi: 10.1007/s12028-008-9088-5.
5
A risk-benefit assessment of aprotinin in cardiac surgical procedures.心脏手术中抑肽酶的风险效益评估。
Drug Saf. 1998 Jan;18(1):21-41. doi: 10.2165/00002018-199818010-00003.
6
Coagulative interventions during angiography.血管造影术中的凝血干预措施。
Cardiovasc Intervent Radiol. 1982;5(1):46-56. doi: 10.1007/BF02552105.
7
Tranexamic acid (AMCA) in aneurysmal subarachnoid haemorrhage.氨甲环酸在动脉瘤性蛛网膜下腔出血中的应用
J Clin Pathol Suppl (R Coll Pathol). 1980;14:68-73.
8
Long-term prognosis of subarachnoid hemorrhages of unknown etiology.不明病因蛛网膜下腔出血的长期预后
J Neurol. 1985;232(5):277-9. doi: 10.1007/BF00313865.
9
Antifibrinolytic agents in subarachnoid haemorrhage.蛛网膜下腔出血中的抗纤溶药物
J Neurol. 1987 Jan;234(1):1-8. doi: 10.1007/BF00314000.
10
Clinical application of inhibitors of fibrinolysis.纤维蛋白溶解抑制剂的临床应用。
Drugs. 1985 Mar;29(3):236-61. doi: 10.2165/00003495-198529030-00003.